Targeted transport of biotherapeutics at the blood-brain barrier

References

• Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood– brain barrier. Neurobiology Of Disease. 2010;37(1):13–25. doi: 10.1016/j.nbd.2009.07.030
   PubMed Web of Science ®Google Scholar
• Hladky SB, Barrand MA. Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the blood–brain barrier. Fluids Barriers CNS. 2018;15(1). doi: 10.1186/s12987-018-0113-6
   PubMedGoogle Scholar
• Pardridge WM. The blood-brain barrier. Bottleneck in brain drug development. NeuroRx. 2005;2(1):3–14. doi: 10.1602/neurorx.2.1.3
   PubMedGoogle Scholar
• Pardridge WM. Advanced blood–brain barrier drug delivery. Pharmaceutics. doi: 10.3390/pharmaceutics15010093
   Web of Science ®Google Scholar
• Zuchero YJ, Chen X, Bien-Ly N, et al. Discovery of novel blood-brain barrier targets to enhance brain uptake of therapeutic antibodies. Neuron. 2016;89(1):70–82. doi: 10.1016/j.neuron.2015.11.024
   PubMed Web of Science ®Google Scholar
• Sonoda H, Morimoto H, Yoden E, et al. A blood-brain-barrier-penetrating anti- human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II. Mol Ther. 2018;26(5):1366–1374. doi: 10.1016/j.ymthe.2018.02.032
   PubMed Web of Science ®Google Scholar
• Niewoehner J, Bohrmann B, Collin L, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014;81(1):49–60. doi: 10.1016/j.neuron.2013.10.061
   PubMed Web of Science ®Google Scholar
• Kariolis MS, Wells RC, Getz JA, et al. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med. 2020;12(545). doi: 10.1126/scitranslmed.aay1359
   Web of Science ®Google Scholar
• Chew KS, Wells RC, Moshkforoush A, et al. CD98hc is a target for brain delivery of biotherapeutics. Nat Commun. 2023;14(1). doi: 10.1038/s41467-023-40681-4
   Web of Science ®Google Scholar
• Barker SJ, Thayer MB, Kim C, et al. Targeting transferrin receptor to transport antisense oligonucleotides across the blood-brain barrier. bioRxiv. doi: 10.1101/2023.04.25.538145
   Google Scholar
• Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. The Journal Of Cell Biology. 1969;3:648–677. doi: 10.1083/jcb.40.3.648
   PubMed Web of Science ®Google Scholar
• Hartmann DA, Berthiaume AA, Grant RI, et al. Brain capillary pericytes exert a substantial but slow influence on blood flow. Nat Neurosci. 2021;24(5):633–645. doi: 10.1038/s41593-020-00793-2
   PubMed Web of Science ®Google Scholar
• Sargent SM, Bonney SK, Li Y, et al. Endothelial structure contributes to heterogeneity in brain capillary diameter. Vasc Biol. 2023;5(1). doi: 10.1530/VB-23-0010
   PubMedGoogle Scholar
• Kadry H, Noorani B, Cucullo L. A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS. 2020;17(1). doi: 10.1186/s12987-020-00230-3
   PubMed Web of Science ®Google Scholar
• Ando Y, Okada H, Takemura G, et al. Brain-specific ultrastructure of capillary endothelial glycocalyx and its possible contribution for blood brain barrier. Sci Rep. 2018;8(1). doi: 10.1038/s41598-018-35976-2
   Google Scholar
• Kutuzov N, Flyvbjerg H, Lauritzen M. Contributions of the glycocalyx, endothelium, and extravascular compartment to the blood–brain barrier. Proc Natl Acad Sci USA. 2018;115(40). doi: 10.1073/pnas.1802155115
   PubMed Web of Science ®Google Scholar
• Coomber BL, Stewart PA. Three-dimensional reconstruction of vesicles in endothelium of blood-brain barrier versus highly permeable microvessels. Anat Rec. 1986;215(3):256–261. doi: 10.1002/ar.1092150308
   PubMedGoogle Scholar
• Noguchi Y, Yamamoto T, Shibata Y. Distribution of endothelial vesicles in the microvasculature of skeletal muscle and brain cortex of the rat, as demonstrated by tannic acid tracer analysis. Cell Tissue Res. 1986. doi: 10.1007/BF00215188 246 3 487–494
   PubMed Web of Science ®Google Scholar
• Roberts RL, Fine RE, Sandra A. Receptor-mediated endocytosis of transferrin at the blood-brain barrier. Journal Of Cell Science. 1993;104(2):521–532. doi: 10.1242/jcs.104.2.521
   PubMedGoogle Scholar
• van Deurs B, Amtorp O. Blood-brain barrier in rats to the hemepetide microperoxidase. Neuroscience. 1978;3(8):737–748. doi: 10.1016/0306-4522(78)90069-6
   PubMed Web of Science ®Google Scholar
• Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. The Journal Of Cell Biology. 1967;34(1):207–217. doi: 10.1083/jcb.34.1.207
   PubMed Web of Science ®Google Scholar
• Toth AE, Holst MR, Nielsen MS. Vesicular transport machinery in brain endothelial cells: what we know and what we do not. CPD. 2020;26(13):1405–1416. doi: 10.2174/1381612826666200212113421
   Google Scholar
• Daneman R, Prat A. The blood–brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1):a020412. doi: 10.1101/cshperspect.a020412
   PubMed Web of Science ®Google Scholar
• Andreone BJ, Chow BW, Tata A, et al. Blood-brain barrier permeability is regulated by lipid transport-dependent suppression of caveolae-mediated transcytosis. Neuron. 2017;94(3):581–594.e5. doi: 10.1016/j.neuron.2017.03.043
   PubMed Web of Science ®Google Scholar
• Kirchhausen T, Owen D, Harrison SC. Molecular structure, function, and dynamics of clathrin-mediated membrane traffic. Cold Spring Harbor Perspectives In Biology. 2014;6(5):a016725–a016725. doi: 10.1101/cshperspect.a016725
   PubMed Web of Science ®Google Scholar
• Thomsen MS, Routhe LJ, Moos T. The vascular basement membrane in the healthy and pathological brain. J Cereb Blood Flow Metab. 2017;37(10):3300–3317. doi: 10.1177/0271678X17722436
   PubMed Web of Science ®Google Scholar
• Del Zoppo GJ, Milner R. Integrin–Matrix Interactions in the Cerebral Microvasculature. Arterioscler Thromb Vasc Biol. 2006;26(9):1966–1975. doi: 10.1161/01.ATV.0000232525.65682.a2
   PubMed Web of Science ®Google Scholar
• Hösli L, Zuend M, Bredell G, et al. Direct vascular contact is a hallmark of cerebral astrocytes. Cell Reports. 2022;39(1):110599. doi: 10.1016/j.celrep.2022.110599
   PubMed Web of Science ®Google Scholar
• Muldoon LL, Pagel MA, Kroll RA, et al. A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery. AJNR Am J Neuroradiol. 1999;20(2): 217–222 . PMID:10094341.
   PubMed Web of Science ®Google Scholar
• Doran SE, Ren XD, Betz AL, et al. Gene expression from recombinant viral vectors in the central nervous system after blood-brain barrier disruption. Neurosurgery. 1995;36(5):965–970. doi: 10.1227/00006123-199505000-00012
   PubMed Web of Science ®Google Scholar
• Thomsen MS, Johnsen KB, Kucharz K, et al. Blood–brain barrier transport of transferrin receptor-targeted nanoparticles. Pharmaceutics. 2022;14(10):2237. doi: 10.3390/pharmaceutics14102237
   PubMed Web of Science ®Google Scholar
• Routhe LJ, Thomsen MS, Moos T. The significance of the choroid plexus for cerebral iron homeostasis. In: Praetorius J, Blazer-Yost B Damkier H, editors. Role of the choroid plexus in health and disease. Physiology in health and disease. (NY) NY: Springer; 2020. doi: 10.1007/978-1-0716-0536-3_5
   Google Scholar
• Bickel U. Modeling blood–brain barrier permeability to solutes and drugs in vivo. Pharmaceutics. 2022;14(8):1696. doi: 10.3390/pharmaceutics14081696
   PubMed Web of Science ®Google Scholar
• Pizzo ME, Wolak DJ, Kumar NN, et al. Intrathecal antibody distribution in the rat brain: surface diffusion, perivascular transport and osmotic enhancement of delivery. The Journal Of Physiology. 2018;596(3):445–475. doi: 10.1113/JP275105
   PubMed Web of Science ®Google Scholar
• Saunders NR, Dziegielewska KM, Møllgård K, et al. Physiology and molecular biology of barrier mechanisms in the fetal and neonatal brain. The Journal Of Physiology. 2018;596(23):5723–5756. doi: 10.1113/JP275376
   PubMed Web of Science ®Google Scholar
• Nakagawa S, Deli MA, Kawaguchi H, et al. A new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochemistry International. 2009;54(3–4):253–263. doi: 10.1016/j.neuint.2008.12.002
   PubMed Web of Science ®Google Scholar
• Thomsen MS, Humle N, Hede E, et al. The blood-brain barrier studied in vitro across species. PLoS One. 2021;16(3):e0236770. doi: 10.1371/journal.pone.0236770.[38]
   PubMed Web of Science ®Google Scholar
• Daneman R, Zhou L, Kebede AA, et al. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature. 2010. doi: 10.1038/nature09513
   PubMed Web of Science ®Google Scholar
• Milner R, Huang X, Wu J, et al. Distinct roles for astrocyte αvβ5 and αvβ8 integrins in adhesion and migration. Journal Of Cell Science. 1999;112(23):4271–4279. doi: 10.1242/jcs.112.23.4271
   PubMed Web of Science ®Google Scholar
• Thomsen MS, Birkelund S, Burkhart A, et al. Synthesis and deposition of basement membrane proteins by primary brain capillary endothelial cells in a murine model of the blood–brain barrier. Journal Of Neurochemistry. 2017;140(5):741–754. doi: 10.1111/jnc.13747
   PubMed Web of Science ®Google Scholar
• Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57(2):173–185. doi: 10.1124/pr.57.2.4
   PubMed Web of Science ®Google Scholar
• Wolburg-Buchholz K, Mack AF, Steiner E, et al. Loss of astrocyte polarity marks blood–brain barrier impairment during experimental autoimmune encephalomyelitis. Acta Neuropathol. 2009;118(2):219–233. doi: 10.1007/s00401-009-0558-4
   PubMed Web of Science ®Google Scholar
• Xu J, Ling EA. Studies of the ultrastructure and permeability of the blood-brain barrier in the developing corpus callosum in postnatal rat brain using electron dense tracers. J Anat. 1994;184(Pt 2): 227–237. PMID: 8014116.
   PubMedGoogle Scholar
• Bär T. Patterns of vascularization in the developing cerebral cortex. Ciba Found Symp. 1983;100:20–36. doi: 10.1002/9780470720813.ch3
   PubMedGoogle Scholar
• Moos T, Oates PS, Morgan EH. Expression of the neuronal transferrin receptor is age dependent and susceptible to iron deficiency. J Comp Neurol. 1998;398(3):420–430. PMID: 9714152. doi: 10.1002/(SICI)1096-9861(19980831)398:3<420:AID-CNE8>3.0.CO;2-1
   PubMed Web of Science ®Google Scholar
• Fisher J, Devraj K, Ingram J, et al. Ferritin: a novel mechanism for delivery of iron to the brain and other organs. American Journal Of Physiology-Cell Physiology. 2007;293(2):C641–C649. doi: 10.1152/ajpcell.00599.2006
   PubMed Web of Science ®Google Scholar
• Li L, Fang CJ, Ryan JC, et al. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci USA. 2010;107(8):3505–3510. doi: 10.1073/pnas.0913192107
   PubMed Web of Science ®Google Scholar
• Andreone BJ, Lacoste B, Gu C. Neuronal and vascular interactions. Annu Rev Neurosci. 2015;38(1):25–46. doi: 10.1146/annurev-neuro-071714-033835
   PubMed Web of Science ®Google Scholar
• Armulik A, Genové G, Mäe M, et al. Pericytes regulate the blood–brain barrier. Nature. 2010;468(7323):557–561. doi: 10.1038/nature09522
   PubMed Web of Science ®Google Scholar
• Betsholtz C, Keller A. PDGF, pericytes and the pathogenesis of idiopathic basal ganglia calcification (IBGC). Brain Pathology. 2014;24(4):387–395. doi: 10.1111/bpa.12158
   PubMed Web of Science ®Google Scholar
• Coelho-Santos V, Shih AY. Postnatal development of cerebrovascular structure and the neurogliovascular unit. Wiley Interdiscip Rev Dev Biol. 2020;9(2). doi: 10.1002/wdev.363
   PubMed Web of Science ®Google Scholar
• van Gelder W, Huijskes-Heins MI, van Dijk JP, et al. Quantification of different transferrin receptor pools in primary cultures of porcine blood-brain barrier endothelial cells. J Neurochem. 1995;64(6):2708–2715. doi: 10.1046/j.1471-4159.1995.64062708.x
   PubMed Web of Science ®Google Scholar
• Moos T, Morgan EH. A morphological study of the developmentally regulated transport of iron into the brain. Dev Neurosci. 2002;24(2–3):99–105. doi: 10.1159/000065702
   PubMed Web of Science ®Google Scholar
• Rouault TA. Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat Rev Neurosci. 2013;14(8):551–564. doi: 10.1038/nrn3453
   PubMed Web of Science ®Google Scholar
• Moos T, Morgan EH. Restricted transport of anti-transferrin receptor antibody (OX26) through the blood–brain barrier in the rat. J Neurochem. 2001;79(1):119–129. doi: 10.1046/j.1471/4159.2001.00541.x
   PubMed Web of Science ®Google Scholar
• Marcos-Contreras OA, Greineder CF, Kiseleva RY, et al. Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood–brain barrier. Proc Natl Acad Sci USA. 2020;117(7):3405–3414. doi: 10.1073/pnas.1912012117
   PubMed Web of Science ®Google Scholar
• Yu YJ, Zhang Y, Kenrick M, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3(84). doi: 10.1126/scitranslmed.3002230
   Web of Science ®Google Scholar
• Stocki P, Szary J, Demydchuk M, et al. CDR3 variants of the TXB2 shuttle with increased TfR1 association rate and enhanced brain penetration. Pharmaceutics. 2023;15(3):739. doi: 10.3390/pharmaceutics15030739
   PubMed Web of Science ®Google Scholar
• Palsa K, Baringer SL, Shenoy G, et al. Exosomes are involved in iron transport from human blood–brain barrier endothelial cells and are modified by endothelial cell iron status. Journal Of Biological Chemistry. 2023;299(2):102868. doi: 10.1016/j.jbc.2022.102868
   PubMed Web of Science ®Google Scholar
• Yang AC, Stevens MY, Chen MB, et al. Physiological blood-brain transport is impaired with age by a shift in transcytosis. Nature. 2020;2453–z. doi: 10.1038/s41586-020-
   Web of Science ®Google Scholar
• Yogi A, Hussack G, van Faassen H, et al. Brain delivery of IGF1R5, a single- domain antibody targeting insulin-like growth factor-1 receptor. Pharmaceutics. 2022;14(7):1452. doi: 10.3390/pharmaceutics14071452
   PubMed Web of Science ®Google Scholar
• Shin JW, An S, Kim D, et al. Grabody B, an IGF1 receptor-based shuttle, mediates efficient delivery of biologics across the blood-brain barrier. Cell Rep Methods. 2022;2(11):100338. doi: 10.1016/j.crmeth.2022.100338
   PubMedGoogle Scholar
• Fan K, Jia X, Zhou M, et al. Ferritin nanocarrier traverses the blood brain barrier and kills glioma. ACS Nano. 2018;12(5):4105–4115. doi: 10.1021/acsnano.7b06969
   PubMed Web of Science ®Google Scholar
• Nästle L, Deuschle FC, Morath V, et al. FerryCalin: an engineered Lipocalin protein directed against the transferrin receptor with potential for brain drug delivery. Chembiochem. 2023;24(10). doi: 10.1002/cbic.202200795
   PubMedGoogle Scholar
• Bien-Ly N, Yu YJ, Bumbaca D, et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. Journal Of Experimental Medicine. 2014;211(2):233–244. doi: 10.1084/jem.20131660
   PubMed Web of Science ®Google Scholar
• Couch JA, Yu YJ, Zhang Y, et al. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med. 2013;5(183):183ra57, 1–12. doi: 10.1126/scitranslmed.3005338
   PubMed Web of Science ®Google Scholar
• Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Advanced Drug Delivery Reviews. 2007;59(8):748–758. doi: 10.1016/j.addr.2007.06.008
   PubMed Web of Science ®Google Scholar
• Johnsen KB, Burkhart A, Thomsen LB, et al. Targeting the transferrin receptor for brain drug delivery. Progress In Neurobiology. 2019;181:101665. doi: 10.1016/j.pneurobio.2019.101665
   PubMed Web of Science ®Google Scholar
• Nielsen SSE, Holst MR, Langthaler K, et al. Apicobasal transferrin receptor localization and trafficking in brain capillary endothelial cells. Fluids Barriers CNS. 2023;20(1). doi: 10.1186/s12987-022-00404-1
   Web of Science ®Google Scholar
• Siupka P, Hersom MN, Lykke-Hartmann K, et al. Bidirectional apical–basal traffic of the cation-independent mannose-6-phosphate receptor in brain endothelial cells. J Cereb Blood Flow Metab. 2017;37(7):2598–2613. doi: 10.1177/0271678X17700665
   PubMed Web of Science ®Google Scholar
• Haqqani AS, Thom G, Burrell M, et al. Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood–brain barrier in vitro is dependent on its binding affinity. J Neurochem. 2018;146(6):735–752. doi: 10.1111/jnc.14482
   PubMed Web of Science ®Google Scholar
• Sade H, Baumgartner C, Hugenmatter A, et al. A human blood-brain barrier transcytosis assay reveals antibody transcytosis influenced by pH-dependent receptor binding. PLoS One. 2014;9(4):e96340. doi: 10.1371/journal.pone.0096340
   PubMed Web of Science ®Google Scholar
• Terstappen GC, Meyer AH, Bell RD, et al. Strategies for delivering therapeutics across the blood–brain barrier. Nat Rev Drug Discov. 2021;20(5):021- 00139–y. doi: 10.1038/s41573-
   Web of Science ®Google Scholar
• Qu M, Lin Q, Huang L, et al. Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson’s disease. Journal Of Controlled Release. 2018;287:156–166. doi: 10.1016/j.jconrel.2018.08.035
   PubMed Web of Science ®Google Scholar
• Chen CC, Liu L, Ma F, et al. Elucidation of exosome migration across the blood- brain barrier model in vitro. Cell Mol Bioeng. 2016;0458–3. doi: 10.1007/s12195-016-
   Web of Science ®Google Scholar
• Stocki P, Szary J, Rasmussen CLM, et al. Blood-brain barrier transport using a high affinity, brain-selective VNAR antibody targeting transferrin receptor 1. FASEB J. 2021;35(2). doi: 10.1096/fj.202001787R
   Web of Science ®Google Scholar
• Georgieva JV, Katt M, Ye Z, et al. The 46.1 antibody mediates neurotensin uptake into the CNS and the effects depend on the route of intravenous administration. Pharmaceutics. 2022;14(8):1706. doi: 10.3390/pharmaceutics14081706
   PubMed Web of Science ®Google Scholar
• Triguero D, Buciak J, Pardridge WM. Capillary depletion method for quantification of blood–brain barrier transport of circulating peptides and plasma proteins. Journal Of Neurochemistry. 1990;54(6):1882–1888. doi: 10.1111/j.1471-4159
   PubMed Web of Science ®Google Scholar
• Hultqvist G, Syvänen S, Fang XT, et al. Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor. Theranostics. 2017;7(2):308–318. doi: 10.7150/thno.17155
   PubMed Web of Science ®Google Scholar
• Kucharz K, Kutuzov N, Zhukov O, et al. Shedding light on the blood–brain barrier transport with Two-Photon Microscopy in vivo. Pharm Res. 2022;39(7):1457–1468. doi: 10.1007/s11095-022-03266-2
   PubMed Web of Science ®Google Scholar
• Holst CB, Brøchner CB, Vitting-Seerup K, et al. The HOPX and BLBP landscape and gliogenic regions in developing human brain. Journal Of Anatomy. 2023;243(1):23–38. doi: 10.1111/joa.13844
   PubMed Web of Science ®Google Scholar
• Wouters Y, Jaspers T, Rué L, et al. Vhhs as tools for therapeutic protein delivery to the central nervous system. Fluids Barriers CNS. 2022;19(1):00374–4. doi: 10.1186/s12987-022-
   Web of Science ®Google Scholar
• Esparza TJ, Su S, Francescutti CM, et al. Enhanced in vivo blood brain barrier transcytosis of macromolecular cargo using an engineered pH-sensitive mouse transferrin receptor binding nanobody. Fluids Barriers CNS. 2023;20(1). doi: 10.1186/s12987-023-00462-z
   PubMedGoogle Scholar
• Johnsen KB, Bak M, Kempen PJ, et al. Antibody affinity and valency impact brain uptake of transferrin receptor-targeted gold nanoparticles. Theranostics. 2018;8(12):3416–3436. doi: 10.7150/thno.25228
   PubMed Web of Science ®Google Scholar
• Kucharz K, Kristensen K, Johnsen KB, et al. Post-capillary venules are the key locus for transcytosis-mediated brain delivery of therapeutic nanoparticles. Nat Commun. 2021;12(1). doi: 10.1038/s41467-021-24323-1
   PubMed Web of Science ®Google Scholar
• Alata W, Yogi A, Brunette E, et al. Targeting insulin-like growth factor-1 receptor (IGF1R) for brain delivery of biologics. The FASEB Journal. 2022;36(3). doi: 10.1096/fj.202101644R
   PubMed Web of Science ®Google Scholar
• Hede E, Christiansen CB, Heegaard CW, et al. Gene therapy to the blood–brain barrier with resulting protein secretion as a strategy for treatment of Niemann Picks type C2 disease. Journal Of Neurochemistry. 2021;156(3):290–308. doi: 10.1111/jnc.14982
   PubMed Web of Science ®Google Scholar
• Rasmussen CLM, Hede E, Routhe LJ, et al. A novel strategy for delivering N iemann- P ick type C2 proteins across the blood–brain barrier using the brain endothelial-specific AAV-BR1 virus. Journal Of Neurochemistry. 2023;164(1):6–28. doi: 10.1111/jnc.15621
   PubMed Web of Science ®Google Scholar
• Helms HC, Abbott NJ, Burek M, et al. In vitro models of the blood–brain barrier: an overview of commonly used brain endothelial cell culture models and guidelines for their use. J Cereb Blood Flow Metab. 2016;36(5):862–890. doi: 10.1177/0271678X16630991
   PubMed Web of Science ®Google Scholar
• Christensen SC, Hudecz D, Jensen A, et al. Basigin antibodies with capacity for drug delivery across brain endothelial cells. Mol Neurobiol. 2021;58(9):4392–4403. doi: 10.1007/s12035-021-02421-x
   PubMedGoogle Scholar
• Manthe RL, Loeck M, Bhowmick T, et al. Intertwined mechanisms define transport of anti-ICAM nanocarriers across the endothelium and brain delivery of a therapeutic. Journal Of Controlled Release. 2020;324:181–193. doi: 10.1016/j.jconrel.2020.05.009
   PubMed Web of Science ®Google Scholar
• Faresjö R, Sehlin D, Syvänen S. Age, dose, and binding to TfR on blood cells influence brain delivery of a TfR-transported antibody. Fluids Barriers CNS. 2023;20(1). doi: 10.1186/s12987-023-00435-2
   PubMed Web of Science ®Google Scholar
• Edavettal S, Cejudo-Martin P, Dasgupta B, et al. Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis. Med. 2022;3(12):860–882.e15. doi: 10.1016/j.medj.2022.09.007
   PubMedGoogle Scholar
• Borges LF, Elliott PJ, Gill R, et al. Selective extraction of small and large molecules from the cerebrospinal fluid by purkinje neurons. Science. 1985;228(4697):346–348. doi: 10.1126/science.2580350
   PubMed Web of Science ®Google Scholar
• Arguello A, Mahon CS, Calvert MEK, et al. Molecular architecture determines brain delivery of a transferrin receptor–targeted lysosomal enzyme. J Exp Med. 2022;219(3). doi: 10.1084/jem.20211057
   PubMed Web of Science ®Google Scholar
• Gehrlein A, Udayar V, Anastasi N, et al. Targeting neuronal lysosomal dysfunction caused by β-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct. Nat Commun. 2023;14(1). doi: 10.1038/s41467-023-37632-4
   PubMed Web of Science ®Google Scholar
• Ullman JC, Arguello A, Getz JA, et al. Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice. Sci Transl Med. 2020;12(545). doi: 10.1126/scitranslmed.aay1163
   Web of Science ®Google Scholar
• Gosk S, Vermehren C, Storm G, et al. Targeting anti—transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J Cereb Blood Flow Metab. 2004;24(11):1193–1204. doi: 10.1097/01.WCB.0000135592.28823.47
   PubMed Web of Science ®Google Scholar
• Campos CR, Kemble AM, Niewoehner J, et al. Brain shuttle neprilysin reduces central amyloid-β levels. PLoS One. 2020;15(3):e0229850. doi: 10.1371/journal.pone.0229850
   PubMed Web of Science ®Google Scholar
• Johnsen KB, Burkhart A, Melander F, et al. Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma. Sci Rep. 2017;7(1):1. doi: 10.1038/s41598-017-11220-1
   PubMedGoogle Scholar
• Kahana M, Weizman A, Gabay M, et al. Liposome-based targeting of dopamine to the brain: a novel approach for the treatment of Parkinson’s disease. Mol Psychiatry. 2021;26(6):2626–2632. doi: 10.1038/s41380-020-0742-4
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yue P, Peng Y, et al. Recent advances in drug delivery systems for targeting brain tumors. Drug Deliv. 2023;30(1):1–18. doi: 10.1080/10717544.2022.2154409
   PubMed Web of Science ®Google Scholar
• D’Souza A, Dave KM, Stetler RA, et al. Targeting the blood-brain barrier for the delivery of stroke therapies. Advanced Drug Delivery Reviews. 2021;171:332–351. doi: 10.1016/j.addr.2021.01.015
   PubMed Web of Science ®Google Scholar
• Baghirov H, Snipstad S, Sulheim E, et al. Ultrasound-mediated delivery and distribution of polymeric nanoparticles in the normal brain parenchyma of a metastatic brain tumour model. PLoS One. 2018;13(1):e0191102. doi: 10.1371/journal.pone.0191102
   PubMed Web of Science ®Google Scholar
• Liu D, Zhu M, Zhang Y, et al. Crossing the blood-brain barrier with AAV vectors. Metab Brain Dis. 2021;36(1):45–52. doi: 10.1007/s11011-020-00630-2
   PubMed Web of Science ®Google Scholar
• Zhou K, Han J, Wang Y, et al. Routes of administration for adeno- associated viruses carrying gene therapies for brain diseases. Front Mol Neurosci. 2022. doi: 10.3389/fnmol.2022.988914
   Web of Science ®Google Scholar
• Körbelin J, Dogbevia G, Michelfelder S, et al. A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases. EMBO Mol Med. 2016;8(6):609–625. doi: 10.15252/emmm.201506078
   PubMed Web of Science ®Google Scholar
• Santisteban MM, Ahn SJ, Lane D, et al. Endothelium-macrophage crosstalk mediates blood-brain barrier dysfunction in hypertension. Hypertension. 2020;76(3):795–807. doi: 10.1161/HYPERTENSIONAHA.120.15581
   PubMed Web of Science ®Google Scholar
• Nikolakopoulou AM, Wang Y, Ma Q, et al. Endothelial LRP1 protects against neurodegeneration by blocking cyclophilin a. Journal Of Experimental Medicine. 2021;218(4). doi: 10.1084/jem.20202207
   PubMed Web of Science ®Google Scholar
• Sundaram SM, Arrulo Pereira A, Müller-Fielitz H, et al. Gene therapy targeting the blood–brain barrier improves neurological symptoms in a model of genetic MCT8 deficiency. Brain. 2022;145(12):4264–4274. doi: 10.1093/brain/awac243
   PubMed Web of Science ®Google Scholar
• Aydin S, Pareja J, Schallenberg VM, et al. Antigen recognition detains CD8+ T cells at the blood-brain barrier and contributes to its breakdown. Nat Commun. 2023;14(1). doi: 10.1038/s41467-023-38703-2
   Web of Science ®Google Scholar
• Kawabata H, Konno A, Matsuzaki Y, et al. A blood-brain barrier-penetrating AAV2 mutant created by a brain microvasculature endothelial cell-targeted AAV2 variant. Molecular Therapy Methods & Clinical Development. 2023;29:81–92. doi: 10.1016/j.omtm.2023.02.016
   PubMed Web of Science ®Google Scholar
• Huang Q, Chen AT, Chan KY, et al. Targeting AAV vectors to the central nervous system by engineering capsid–receptor interactions that enable crossing of the blood–brain barrier. PLoS Biol. 2023;21(7):e3002112. doi: 10.1371/journal.pbio.3002112
   PubMed Web of Science ®Google Scholar
• Graßhoff H, Müller-Fielitz H, Dogbevia GK, et al. Short regulatory DNA sequences to target brain endothelial cells for gene therapy. J Cereb Blood Flow Metab. 2022;42(1):104–120. doi: 10.1177/0271678X211039617
   PubMed Web of Science ®Google Scholar
• Xie R, Wang Y, Burger JC, et al. Non-viral approaches for gene therapy and therapeutic genome editing across the blood–brain barrier. Med X. 2023;1(1). doi: 10.1007/s44258-023-00004-0
   PubMedGoogle Scholar
• Pardridge WM. Brain gene therapy with Trojan horse lipid nanoparticles. Trends Mol Med. 2023. doi: 10.1016/j.molmed.2023.02.004
   PubMed Web of Science ®Google Scholar
• Burkhart A, Thomsen LB, Thomsen MS, et al. Transfection of brain capillary endothelial cells in primary culture with defined blood–brain barrier properties. Fluids Barriers CNS. 2015;12(1). doi: 10.1186/s12987-015-0015-9
   PubMedGoogle Scholar
• Lichota J, Skjørringe T, Thomsen LB, et al. Macromolecular drug transport into the brain using targeted therapy. J Neurochem. 2010. doi: 10.1111/j.1471-4159.2009.06544.x
   PubMed Web of Science ®Google Scholar
• Ma F, Yang L, Sun Z, et al. Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection. Sci Adv. 2020;6(30). doi: 10.1126/sciadv.abb4429
   Web of Science ®Google Scholar